- Home
- Automated
- List of product information
- CRINONE PROGESTERONE VAGINAL GEL 8% [SIN10884P]
CRINONE PROGESTERONE VAGINAL GEL 8% [SIN10884P]
Active ingredients: CRINONE PROGESTERONE VAGINAL GEL 8%
Last updated 26 October 2025
On this page
Product Info
CRINONE PROGESTERONE VAGINAL GEL 8%
[SIN10884P]
Product information
Active Ingredient and Strength | PROGESTERONE - 8% |
Dosage Form | GEL |
Manufacturer and Country | DENDRON BRANDS LTD - UNITED KINGDOM |
Registration Number | SIN10884P |
Licence Holder | MERCK PTE. LTD. |
Forensic Classification | PRESCRIPTION ONLY MEDICINES |
Anatomical Therapeutic Chemical (ATC) code | G03DA04 |
Therapeutic Indications
Treatment of disorders associated with progesterone deficiency, such as:
infertility due to inadequate luteal phase.
for use during in-vitro fertilisation, where infertility is mainly due to tubal, idiopathic or endometriosis linked sterility associated with normal ovulatory cycles.
Posology and method of administration
Intravaginal application
Treatment of infertility due to inadequate luteal phase: one application (1.125 g 8 % gel) every day, starting after documented ovulation or arbitrarily on the 18th–21st day of the cycle.
When used during in-vitro fertilisation, daily application of Crinone® 8 % gel should be continued for 30 days if there is laboratory evidence of pregnancy. Children: not applicable.
Contra-indications
known sensitivity to Crinone® (progesterone or any of the other ingredient)
undiagnosed vaginal bleeding
known or suspected malignancy of the breast or genital organ
acute porphyria
thrombophlebitis, thromboembolic disorders, cerebral apoplexy or patients with a history of these conditions
missed abortion